AR059581A1 - Procedimientos para el tratamiento de degeneracion macular y afecciones oculares relacionadas - Google Patents

Procedimientos para el tratamiento de degeneracion macular y afecciones oculares relacionadas

Info

Publication number
AR059581A1
AR059581A1 ARP070100700A ARP070100700A AR059581A1 AR 059581 A1 AR059581 A1 AR 059581A1 AR P070100700 A ARP070100700 A AR P070100700A AR P070100700 A ARP070100700 A AR P070100700A AR 059581 A1 AR059581 A1 AR 059581A1
Authority
AR
Argentina
Prior art keywords
macular degeneration
procedures
treatment
related ocular
affections
Prior art date
Application number
ARP070100700A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR059581A1 publication Critical patent/AR059581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP070100700A 2006-02-21 2007-02-19 Procedimientos para el tratamiento de degeneracion macular y afecciones oculares relacionadas AR059581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77552006P 2006-02-21 2006-02-21

Publications (1)

Publication Number Publication Date
AR059581A1 true AR059581A1 (es) 2008-04-16

Family

ID=38226652

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100700A AR059581A1 (es) 2006-02-21 2007-02-19 Procedimientos para el tratamiento de degeneracion macular y afecciones oculares relacionadas

Country Status (4)

Country Link
JP (1) JP2007224032A (fr)
AR (1) AR059581A1 (fr)
TW (1) TW200744670A (fr)
WO (1) WO2007096744A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107753A1 (fr) * 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 Liposome pour une administration au segment postérieur de l'œil et composition pharmaceutique pour une maladie du segment postérieur de l'œil
EP3445335A4 (fr) * 2016-04-19 2020-03-04 Nanyang Technological University Formulations formant un dépôt sous-conjonctival pour l'administration de médicament au niveau de l'oeil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141018A1 (de) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
WO2007038549A1 (fr) * 2005-09-26 2007-04-05 Vasogen Ireland Limited Traitement d'inflammations et d'anomalies vasculaires de l'oeil

Also Published As

Publication number Publication date
JP2007224032A (ja) 2007-09-06
TW200744670A (en) 2007-12-16
WO2007096744A1 (fr) 2007-08-30

Similar Documents

Publication Publication Date Title
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
CR20130432A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR059555A1 (es) Metodos para el tratamiento de degeneracion macular y condiciones oculares relacionadas
ECSP12011857A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
BR112013017316A2 (pt) compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SV2008002967A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
ECSP10010112A (es) Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa
BRPI0811142A8 (pt) prevenção e tratamento de condições oculares associadas a complementos
GT200500360A (es) Compuestos organicos
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
ECSP10010346A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
SV2008003032A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112013028666A2 (pt) compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0510778A (pt) composição farmacêutica, processo para a preparação da mesma, método para o tratamento de rinite, e, uso de uma composição

Legal Events

Date Code Title Description
FA Abandonment or withdrawal